Search Results - "Demirkazık, A"

The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey by Kilickap, S., Ölmez, ÖF., Cicin, I., Demirci, U., Alan, O., Cabuk, D., Şakalar, T., Tatlı, A.M., Başol Buğdaycı, F., Eralp, Y., Uysal, M., Demirkazık, A., Bilgin, B., Yıldız, B., Karaağaç, M., Okutur, K., Sakin, A.

Get full text

The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer by Ürun, Y, Utkan, G, Yalcin, B, Akbulut, H, Onur, H, Oztuna, D G, Şenler, F C, Demirkazık, A, İçli, F

“…Identification of patient with increased risk of cardiotoxicity would allow not only prevention and early diagnosis of chemotherapy related cardiotoxicity but…”
Get more information

P0146 The prognostic role of XRCC1 , ERCC1 , ERCC2 , and TP53 single nucleotide polymorphisms in resected non-small-cell lung cancer by Geredeli, C, Artac, M, Yildirim, S, Dede, I, Inal, A, Guler, T, Boruban, M.C, Zamani, A, Bozcuk, H, Demirkazik, A

“…Background Identification of biomarkers that can be used for the prognostic evaluation of NSCLC patients is important. The aim of this study was to evaluate…”
Get full text

Role of ABCB1 and ABCC1 Gene Induction on Survival in Locally Advanced Breast Cancer by Atalay, C., Demirkazik, A., Gunduz, U.

“…Drug resistance to chemotherapy in patients with locally advanced breast cancer results in a decrease in treatment efficacy and in patient survival. This study…”
Get full text

1401PThe efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey by Kilickap, S, Ölmez, Ö F, Cicin, I, Demirci, U, Alan, O, Cabuk, D, Şakalar, T, Tatlı, A M, Başol Buğdaycı, F, Eralp, Y, Uysal, M, Demirkazık, A, Bilgin, B, Yıldız, B, Karaağaç, M, Okutur, K, Sakin, A

Get full text

Perception about influenza and pneumococcal vaccines and vaccination coverage among patients with malignancies and their family members by Urun, Y, Akbulut, H, Demirkazik, A, Cay Senler, F, Utkan, G, Onur, H, Icli, F

“…Although influenza and pneumococcal vaccinations for high-risk populations are recommended by current guidelines, vaccination coverage rate (VCR) is still low…”
Get more information

9091 POSTER Quality of Life Assesment in Patients With Non-Small Cell Lung Cancer Patients Who Have or Have Not Received Second Line Chemotherapy by Yalcin, B, Suna, N, Dogan, M, Urun, Y, Özdemir, N, Gonullu, U, Zengin, N, Utkan, G, Demirkazik, A, Igli, F

Get full text

6135 POSTER Relationship Between ABO and RH Blood Groups and K-Ras Phenotype in Patients With Colorectal Adenocarcinoma by Urun, Y, Utkan, G, Arslan, O, Akbulut, H, Savas, B, Senler, F.C, Onur, H, Yalcin, B, Demirkazik, A, Icli, F

Get full text

Medical oncologists' attitudes towards vaccination in oncology practice by Alkan, A., Karcı, E., Yaşar, A., Tuncay, G., Ürün, M., Köksoy, E.B., Ürün, Y., Şenler, F. Çay, Utkan, G., Demirkazık, A., Akbulut, H.

Get full text

Adjuvant concurrent chemoradiotherapy(CRT) plus docetaxel- cisplatin- fluorouracil (DCF) versus CRT plus fluorouracil folinic acid (FUFA) in gastric cancer by Alkan, A., Mızrak, D., Karcı, E., Yaşar, A., Köksoy, E.B., Ürün, M., Kütük, T., Ürün, Y., Şenler, F. Çay, Akyürek, S., Utkan, G., Demirkazık, A., Gökçe, Ş.Ç., Akbulut, H.

Get full text

9067 POSTER The Significance of the Serum Leptin, Ghreline, Tumour Necrosis Factor Alpha and lnterleukine-1 Levels in Patients With Non-Small Cell Lung Cancer by Urun, Y, Yalcin, B, Karatas, F, Utkan, G, Yuksel, C, Cangir, A.K, Senler, F.C, Demirkazik, A, Akbulut, H, Icli, F, Sencan, O

Get full text

The effects of magnetic field on the biomechanics parameters of soleus and extensor digitorum longus muscles in rats with streptozotocin-induced diabetes by Pelit, A, Ozaykan, B, Tuli, A, Demirkazik, A, Emre, M, Günay, I

“…The aim of this study was to determine the effects of the magnetic field (MF) on the isometric contractile characteristics of the soleus and extensor digitorum…”
Get more information

ABO and Rh blood groups frequency in women with HER2 positive breast cancer by Urun, Y, Utkan, G, Altundag, K, Arslan, O, Onur, H, Arslan, U Y, Kocer, M, Dogan, I, Senler, F C, Yalcin, B, Demirkazik, A, Akbulut, H, Icli, F

“…The role of genetic factors in the development of cancer is widely accepted. Data on the role of ABO blood group and Rh factor in breast cancer is…”
Get more information

Antinociceptive Effects in Normal and Diabetic Rats Exposed to 50 Hz Magnetic Field by Kosar, M. I., Demir, T., Demirkazik, A., Deveci, K., Ozdemir, E., Gulturk, S.

“…The effects of repeated applications of alternating sinusoidal 50 Hz magnetic field, MF (B = 5.0 mT, 165-minlong sessions everyday, each including four…”
Get full text

Ultrasound-guided percutaneous laser ablation treatment in inoperable aggressive course anaplastic thyroid carcinoma: the introduction of a novel alternative palliative therapy--second experience in the literature by Cakir, B, Topaloglu, O, Gul, K, Agac, T, Aydin, C, Dirikoc, A, Ersoy, R U, Gumus, M, Yazicioglu, K, Yalcin, B, Demirkazik, A, Icli, F, Ceyhan, K

Get full text

Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group by ICLI, F, AKBULUT, H, SENLER, F. C, SENCAN, O, BÜYÜKSELIK, A, BORUBAN, C, ONUR, H, ZENGIN, N, SAK, S. D, UNER, A, YALCIN, B, BALTALI, E, ALTINBAS, M, COSKUN, S, KOMURCU, S, ERKISI, M, DEMIRKAZIK, A

“…Our objective was to determine whether oral etoposide and cisplatin combination (EoP) is superior to paclitaxel in the treatment of advanced breast cancer…”
Get full text

Interferon-alpha as maintenance therapy in patients with multiple myeloma by Yalcin, B., Dogan, M., Buyukcelik, A., Doruk, H., Tek, I., Demirkazik, A.

Get full text

metastatic liver tumour with unusual cytological findings by Ceyhan, K, Yalcin, B, Ustuner, E, Percinel, S, Demirkazik, A, Umudum, H

Get full text

The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma by SENCAN, O., BUYUKCELIK, A., YALCIN, B., BORUBAN, M.C., AKBULUT, H., DEMIRKAZIK, A., SENLER, F.C., ONUR, H., ICLI, F.

“…There are few reports on use of symptomatic benefits as an alternative or adjunctive for the assessment of objective response in chemotherapy of the advanced…”
Get full text

19P Predictors of osimertinib response at second-line treatment in EGFR mutant non-small cell lung cancer patients with acquired T790M resistance mutation by Dogan, I., Gürbüz, M., Paksoy, N., Khanmamadov, N., Vatansever, S., Saip, P., Demirkazik, A., Aydiner, A.

Get full text